Batoclimab, a experimental antibody targeting the IL-15 pathway, is gaining attention as a encouraging clinical option for individuals diagnosed with moderate to severe ulcerative colitis and have not responded https://batoclimab-preclinical-d496663.blogdigy.com/batoclimab-a-exciting-new-therapy-for-inflammatory-bowel-disease-69610315